The improved response of patients with KRAS wild-type tumours treated with anti-EGFR therapy has been well documented in the literature (Cunningham et al, 2004; Karapetis et al, 2008; Van Cutsem et al, 2009; Douillard et al, 2010; Peeters et al, 2010; Bokemeyer et al, 2011). Here, KRAS is linked to neoplasm.